Depakote Lawsuit Attorneys of Williams Kherkher Discuss Recent News About Abbott Labs

(LegalLaw247.com, November 08, 2011 ) Houston, TX -- According to a story published in the New York Times on October 19th, 2011, Abbot Labs, the creator of many medical devices and drugs (including Depakote), will split into two separate companies next year. The division is intended to separate the part of the company that creates pharmaceuticals from the part that creates medical devices so that shareholders and investors can decide where they want their support to go.

Individuals who are considering legal action against the manufacturer of Depakote may need to know about this split, according to the Depakote lawsuit attorneys of Williams Kherkher. Depakote, a drug used for depression, bipolar disorder, and seizure treatment, may be linked to devastating health problems for children born to mothers on the medication. Families suffering from serious birth defects may be eligible for financial compensation if they have suffered due to a defective pharmaceutical produced by Abbot Labs.

Abbot Labs is a well-established name in the medical community, and the split is expected to help stockholders and potential investors make decisions about their finances. Although the name of the company may change during this split, victims of Depakote-related accidents may still be able to take legal action against Abbot Labs.

About Williams Kherker

Williams Kherkher is a mass-tort law firm based in Houston, Texas, offering legal assistance to clients nationwide. The firm handles a variety of cases, including those involving personal injury law, mesothelioma, and defective pharmaceuticals. For more information about Depakote side effects, alternative treatment options, and your rights as a victim, contact a Depakote lawyer of Williams Kherkher at 800-641-9810 or visit the website http://www.depakotelawsuitcounsel.com.

Press Release Courtesy of Online PR Media: http://bit.ly/tGOP3v


Stafford Burns
800-761-3187
mail@williamskherkher.com

Source: EmailWire.Com